Scholay

学术搜索 · AI 审稿 · LaTeX 协作

Pamela A. Trail

机构：Ophthalmic Consultants of Long Island · ORCID：0009-0006-2551-793X

发表论文 127 篇 · 总被引 8736 次 · h-index 32

代表论文

  • Abstract 2622: TUB-040, a novel Napi2b-targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans (2024 · Cancer Research · 被引 7)
  • TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile (2025 · Molecular Cancer Therapeutics · 被引 6)
  • Abstract 2623: Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugation chemistry, shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index (2024 · Cancer Research · 被引 3)
  • Abstract 2297: Effects of AVA-291 (d3-testosterone) versus testosterone on MCF-7 estrogen receptor positive breast cancer cells - lack of aromatization to estradiol leads to a highly differentiated cellular proliferation profile (2026 · Cancer Research)
  • Supplementary Figure 10 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile (2025)
  • Supplementary Figure 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile (2025)